Overview of Ampidexalone

What is Ampidexalone? (Overview)

Ampidexalone is a fixed-dose combination drug engineered for systemic administration, typically as a solution prepared for injection. It is fundamentally a composite product, designed to provide a simultaneous therapeutic approach against microbial pathogens and excessive host inflammation.

Quick Facts

Property	Description
Active Ingredients	Ampicillin, Colistimethate Sodium, Dexamethasone
Form	Sterile Powder for Solution/Suspension (for injection)
Pharmacological Class	Combination Anti-infective and Glucocorticoid
Common Use Rationale	Management of bacterial infections complicated by acute inflammation
Origin	Synthetic/Semi-synthetic

What is Ampidexalone and What Type of Medicine is It?

Ampidexalone is officially classified as a combination anti-infective and glucocorticoid, a unique composition differentiating it from single-agent treatments that address only infection or inflammation alone. The components are either derived from microbial sources and chemically modified (Ampicillin, Colistimethate Sodium) or fully synthesized (Dexamethasone), placing its origin in the semi-synthetic and synthetic categories. Its application is clinically recognized for intervening in severe infectious processes that require immediate systemic stabilization.

Composition: What Active Ingredients Does Ampidexalone Contain?

The medication contains three key active ingredients: Ampicillin, Colistimethate Sodium, and Dexamethasone. This composition is typically presented as a sterile powder or suspension designed for injection. The formula unites Ampicillin, an aminopenicillin antibiotic, and Colistimethate Sodium, a polymyxin antibiotic, targeting a wide array of bacterial types. This class is utilized for infections caused by certain multi-drug resistant Gram-negative bacilli. The final ingredient, Dexamethasone, is a potent synthetic glucocorticoid, included to actively modulate the inflammatory response.

What is the General Purpose of This Combination Drug?

The general purpose of Ampidexalone is to manage serious systemic infectious processes where the host's inflammatory reaction is pronounced and potentially harmful. The combination is leveraged because the dual antibacterial action provides extensive microbial coverage, while the steroid component works to suppress excessive systemic inflammation. This design ensures the drug is equipped to address both the microbial cause and the consequences of the host's reaction simultaneously.

Regulatory References

What side effects are possible with Ampidexalone?

Ampidexalone: Possible Side Effects and Safety Information

The safety profile for Ampidexalone, based on regulatory documentation, involves a range of documented adverse reactions and specific safety limitations.

Common and Key Adverse Reactions

Adverse reactions that have been reported frequently (in 20% of patients in clinical settings) include rash, nail toxicity (such as paronychia), infusion-related reactions (IRR), musculoskeletal pain, stomatitis, edema, fatigue, and gastrointestinal effects (including constipation, diarrhea, nausea, and vomiting). Common laboratory abnormalities include decreases in albumin, sodium, potassium, hemoglobin, neutrophils, and leukocytes, along with increases in liver enzymes (ALT, AST, GGT).

Serious and Clinically Significant Risks

The most serious safety concerns identified in official labeling include Interstitial Lung Disease (ILD) / Pneumonitis, which requires immediate withholding of the drug if suspected and permanent discontinuation if confirmed. Other serious risks are Venous Thromboembolic (VTE) Events, severe dermatological toxicities (including rare cases of Toxic Epidermal Necrolysis or TEN), and Ocular Toxicity. Managing these events often requires dosage modification or permanent discontinuation based on the severity of the reaction.

Safety Restrictions and Population Considerations

Ampidexalone carries a risk of Embryo-Fetal Toxicity. Females of reproductive potential must be advised to use effective contraception. Additionally, official documents state that lactation should be avoided during treatment. The drug's safety profile is managed through specific monitoring protocols for ILD and worsening eye symptoms, with mandatory dose adjustments for severe, non-resolving adverse reactions.

Overdose and Emergency Response

Ampidexalone overdose involves documented risks associated with its three components. Excessive exposure to the polymyxin component, Colistimethate Sodium, may lead to official neurotoxic effects, including severe neuromuscular blockade, muscle weakness, and apnea. The most serious outcomes noted in regulatory documents include respiratory paralysis and the development of acute renal failure.

Overdose with the Ampicillin component is associated with gastrointestinal effects, such as nausea and diarrhea, and may also involve the risk of convulsions. For the steroid component, Dexamethasone, chronic excessive exposure is documented to cause the physiological finding of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and the clinical presentation of Cushing's syndrome.

In all suspected cases, regulatory instructions mandate that individuals seek immediate medical attention and contact emergency medical services immediately. Management is generally defined as symptomatic and supportive, often requiring hospital monitoring.

Specific official interventions include measures to support respiration, which may necessitate mechanical ventilation for paralysis. Monitoring should focus on the evaluation of renal function and observation for signs of neuromuscular blockade. No specific antidote is known for the Ampicillin or Dexamethasone components, and procedures like hemodialysis are noted as having limited effectiveness for Colistimethate Sodium toxicity.

Therapeutic Uses of Ampidexalone

What Ampidexalone Treats: Main Uses and Benefits

Ampidexalone is used to provide supportive management in clinical situations where a serious bacterial infection is generally accompanied by a severe and noticeable inflammatory reaction. Its use is considered relevant in contexts involving heightened systemic burden, where supporting functional stability may be appropriate.

This medication is applied in the context of serious, systemic bacterial infections, including those that affect major organs or the bloodstream. For example, the component Ampicillin is used to treat certain infections of the lungs, blood, and urinary tract, including conditions like meningitis. The combination of its components includes an agent considered relevant for managing infections caused by certain multi-drug resistant Gram-negative bacteria. This provides the primary benefit of support for managing both types of pathogens that assists with addressing the acute symptomatic burden.

Ampidexalone is used for managing the pronounced symptoms of acute systemic inflammation that accompany severe infection. These symptoms are often related to heightened physiological activity, such as high fever, severe malaise, and extensive local swelling indicative of an inflammatory state. The medication generally supports the process of easing this inflammatory activity, thereby helping to ease the overall symptom burden. It is often applied in clinical settings that involve acute or unstable symptom patterns, such as those that may require short-term symptomatic assistance.

“The approach of simultaneously addressing severe infection and associated inflammation may assist with functional stability during phases when symptoms become more noticeable.”

Quick Fact: Relief for Acute Symptomatic Strain

Ampidexalone is commonly used across conditions presenting with acute episodes and provides support that helps ease the overall symptom burden associated with systemic bacterial disease and its disruptive inflammatory consequences.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Ampidexalone?

Official regulatory documents define strict population eligibility rules for Ampidexalone, primarily based on contraindications related to its active components.

Populations Prohibited from Use (Contraindicated)

Use is strictly prohibited for patients with a documented history of hypersensitivity to any of its components, including Ampicillin, Colistimethate Sodium, or Dexamethasone. It is formally contraindicated in individuals with active, untreated systemic fungal infections and in those with an established diagnosis of Myasthenia Gravis.

Restricted or Conditional Use

The medicine is generally not recommended for patients with severe renal impairment due to the elevated risk of toxicity from the Colistimethate component; conditional use requires intense monitoring. Similarly, patients with uncontrolled Diabetes Mellitus or active peptic ulcer disease require careful management due to the glucocorticoid component.

Age and Reproductive Status

Use in pediatric patients under 12 years of age is not established and is therefore generally not recommended. For older adults (65 years and over), mandatory monitoring of renal function is required. Ampidexalone is also not recommended for use during pregnancy or breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Officially documented interactions for Ampidexalone are classified by regulatory authorities into prohibited combinations, pharmacokinetic changes, and additive pharmacodynamic effects. Co-administration with Live Virus Vaccines is formally restricted when the Dexamethasone component is administered at immunosuppressive doses. Separately, the concurrent use of Sodium Cephalothin is officially discouraged as it is documented to enhance the nephrotoxicity associated with the Colistimethate component.

Pharmacokinetic Interactions

The clearance of Dexamethasone is highly sensitive to CYP3A4 Inducers (such as Rifampin), which can reduce systemic exposure, and CYP3A4 Inhibitors (such as Ketoconazole), which may increase exposure. The antibiotic Ampicillin’s excretion is significantly delayed, resulting in an increased blood level, when co-administered with Probenecid due to inhibition of renal transporters. A high-fat, high-calorie meal is also documented to reduce the peak plasma concentration of Dexamethasone.

Pharmacodynamic Interactions

These interactions involve an additive risk of toxicity. The label notes that co-administration with other Nephrotoxic Agents (such as Aminoglycosides) increases the risk of renal injury. There is also a documented risk of potentiating the neuromuscular blocking effect when used with Curariform Muscle Relaxants. Furthermore, concurrent use of Potassium-Depleting Agents or Nonsteroidal Anti-inflammatory Drugs (NSAIDs) officially increases the risk of hypokalemia and gastrointestinal bleeding, respectively. The label also notes that impaired renal function increases the possibility of apnea when using the Colistimethate component.

Mechanism of Action

Ampidexalone is a combination pharmacologic agent containing Ampicillin, Colistin, and Dexamethasone, each acting through distinct mechanistic pathways.

Ampicillin, a beta-lactam antibiotic, functions as an inhibitor of bacterial cell wall synthesis. It acylates and inactivates membrane-bound Penicillin-Binding Proteins (PBPs), which are transpeptidases essential for cross-linking peptidoglycan polymers in the late stages of cell wall biosynthesis. This structural disruption triggers the activation of bacterial cell wall autolytic enzymes, leading to the osmotic lysis of the bacterial cell.

Colistin, a polymyxin polypeptide, exerts a bactericidal effect by binding to the anionic lipopolysaccharide of the outer membrane of Gram-negative bacteria. This interaction disrupts the membrane's integrity, increasing its permeability and causing the leakage of intracellular contents.

Dexamethasone, a synthetic glucocorticoid, acts as an agonist for the intracellular glucocorticoid receptor. Receptor binding induces conformational changes, resulting in the translocation of the complex to the nucleus, where it modulates the transcription of various genes. This action inhibits multiple pro-inflammatory signaling cascades, primarily by suppressing the synthesis of inflammatory mediators and stabilizing cellular membranes.

Dosage and Administration Information

How Ampidexalone is Used: Official Administration Guidelines

Ampidexalone is supplied as a sterile powder that requires specific preparation prior to administration in a clinical setting. The medication is delivered systemically via parenteral routes and is approved for use through intravenous (IV) injection/infusion or via intramuscular (IM) injection.

The standard total daily dose is calculated primarily based on the Ampicillin component. This dose is administered in divided portions, typically scheduled every 6 or 8 hours. The standard adult dose range for systemic use is generally 1.5 g to 4.5 g of Ampicillin equivalent, with maximum daily limits established for severe infections.

Proper use requires the immediate reconstitution of the sterile powder with a specified diluent, followed by further dilution before administration as an intravenous infusion. The IV dose must be administered slowly, typically over a period of 30 to 60 minutes. Any solution remaining unused in the single-use vial must be immediately discarded after administration.

Dosing requires modification for specific patient groups. A reduction in the dose or frequency is mandatory for patients with renal impairment when creatinine clearance is below 50 mL/min, following established guidelines. The duration of therapy is generally a short course. If the treatment course extends beyond a brief duration, the Dexamethasone component may require a gradual reduction (tapering) upon cessation of therapy to align with prescribing recommendations.

Recent Clinical Evidence

Ampidexalone: Recent Clinical Evidence

Evidence for Use in Severe Systemic Bacterial Infections

Research exploring the anti-infective components of Ampidexalone was studied for use in conditions associated with acute or disruptive episodes, particularly those involving high-severity bacterial infections. These studies, which included limited comparative trials and retrospective observational data, monitored outcomes related to clinical status and bacteriological changes, alongside measures of patient survival. Since Ampidexalone is a fixed combination, the evidence is derived from studies evaluating related antibiotic strategies, rather than the specific triple-drug product itself. Findings describe patterns observed in the studies related to how microbiological changes evolved in the observed populations.

Evidence for Use in Infections Complicated by Acute Systemic Inflammation

The dual therapeutic approach was studied for infectious states with severe, accompanying inflammation. The research consists primarily of Systematic Reviews and Meta-analyses that synthesize data from many prior trials examining the general concept of combining antibiotics with a glucocorticoid. These research scenarios monitored outcomes related to systemic or functional imbalance, such as hemodynamic stability, and tracked overall short-term mortality rates. The evidence is considered bridging evidence and shows that measured outcomes were sensitive to variables such as the specific timing and dosage of the glucocorticoid component used.

Research Limitations and Uncertainty

Dedicated Randomized Controlled Trials (RCTs) specifically examining the final, fixed-dose formulation remain limited, meaning comparative evidence is lacking for the specific combination. Long-term effects are not fully established because the follow-up durations were typically limited. Few data are available for how the combination performs in patient groups outside of critically ill adults, such as children or older adults. Overall, certainty remains low in areas where research still is ongoing.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ampidexalone (FAQ)

Q: Is Ampidexalone known to cause weight gain?

Regulatory documents indicate that weight gain is a reported adverse reaction. This effect is associated with the Dexamethasone component, which can lead to increased appetite and fluid retention, or edema. These are important facts included in the official safety information.

Q: Do I need to avoid certain foods or drinks while taking Ampidexalone?

Official labeling documents warn that the blood concentration of the Dexamethasone component may be reduced when co-administered with a high-fat, high-calorie meal. The official guidance advises that administration be handled with care. Detailed guidance on food and drink interactions is available in the official product information.

Q: Why is Ampidexalone sometimes described as a 'first-in-class' medicine?

Regulatory agencies classify Ampidexalone as a unique combination anti-infective and glucocorticoid. Its purpose is to address both microbial infection and associated host inflammation simultaneously. This specific composition is what makes the product unique compared to single-agent treatments.

Q: What is the shelf life of Ampidexalone tablets?

Ampidexalone is supplied as a sterile powder for injection, not as an oral tablet. The specific shelf life for the unopened sterile powder vial is documented on its official labeling. Official storage guidelines require the product to be kept under strict conditions, such as being protected from light.

Q: Does Ampidexalone interact with herbal supplements like St. John's Wort?

Regulatory documents warn against co-administration with strong CYP3A4 Inducers, which are substances that can reduce the effectiveness of Dexamethasone. Caution is advised, as herbal supplements like St. John's Wort may impact the drug's effectiveness.

Q: What specific conditions is Ampidexalone approved to treat?

Ampidexalone is approved for managing specific, severe systemic bacterial infections. The drug is indicated for use when the infection is also accompanied by a pronounced inflammatory response.

Q: Are there any special blood tests needed while taking Ampidexalone?

Official safety protocols require mandatory monitoring of renal (kidney) function, especially for older patients. Official guidance indicates that blood tests are necessary to monitor for common documented laboratory abnormalities, such as changes in potassium, sodium, liver enzymes (ALT/AST), and blood sugar levels.

Q: Is Ampidexalone considered a high-risk medication?

The medicine is generally prescribed for serious systemic infectious processes. Official labeling identifies a range of Serious and Clinically Significant Risks, including rare events like Interstitial Lung Disease and Venous Thromboembolic Events.

Q: Why do official materials recommend careful use with certain heart medications?

Official materials advise caution when Ampidexalone is used with certain heart medications classified as Potassium-Depleting Agents (such as some diuretics). Official warnings state that concurrent use increases the risk of developing hypokalemia, or low potassium levels.

Q: Can I take other cold or flu medicines with Ampidexalone?

Many over-the-counter cold and flu products contain ingredients like Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Regulatory documents warn that using NSAIDs concurrently increases the risk of gastrointestinal bleeding. It is important to review all combinations of medicines against the official interaction information.

Q: How quickly should I expect Ampidexalone to start working?

Information indicates that the Dexamethasone component is fast-acting, often reaching its peak concentration in the body within approximately one hour after administration. The clinical effect depends on how quickly the overall drug combination addresses the infection and inflammation.

Q: Are there any known drug interactions with birth control pills and Ampidexalone?

Official product information notes interactions with hormonal contraceptives, including birth control pills, as a concern. The Ampicillin component may theoretically reduce the effectiveness of estrogen-containing contraceptives. Official product information should be consulted regarding the need for additional non-hormonal contraception.

Q: Can Ampidexalone affect my sleep?

Yes, sleep problems are a documented adverse reaction in the official safety profile. Specifically, insomnia (difficulty sleeping) is commonly reported as a side effect associated with the Dexamethasone component of the drug.

Q: Do official documents mention any warnings about driving while on Ampidexalone?

Regulatory documents list potential side effects such as changes in mood, confusion, and Ocular Toxicity (vision issues). Given these potential effects, it is necessary to be aware of how the medicine affects you before operating heavy machinery or driving.

Q: Can Ampidexalone cause changes in mood or anxiety?

The Dexamethasone component is known to affect mental health. Official records state that side effects can include changes in mood, restlessness, depression, and anxiety.

Q: Are there different brand names for the Ampidexalone compound?

Regulatory documents, such as those published by the FDA or EMA, list the approved trade or brand name(s) under which Ampidexalone is commercially marketed. It is a prescription-only medicine.

Q: Is Ampidexalone safe for people with liver problems?

Official documents indicate that patients with pre-existing liver problems require careful use and monitoring. The label reports increases in liver enzymes and lists liver damage as a possible serious side effect. Specific cautions apply, particularly for the Dexamethasone and Colistin components.

Q: How is Ampidexalone absorbed by the body?

Ampidexalone is designed to be administered systemically via parenteral routes, meaning it is given by injection or infusion (intravenous or intramuscular). The specific time-course and extent of the drug's absorption are detailed in the clinical pharmacology section of the labeling.

Q: Is Ampidexalone an addictive substance?

No. Official regulatory scheduling confirms that Ampidexalone and its active components (Ampicillin, Colistin, and Dexamethasone) are not classified as controlled substances. There is no designation for abuse potential.

Q: Does alcohol use affect the safety of Ampidexalone?

Regulatory guidance advises against combining Ampidexalone with agents that increase the risk of gastrointestinal irritation. It is generally advisable to exercise caution when using alcohol with prescription medications.

How should Ampidexalone be stored and disposed of?

How to Store and Dispose of Ampidexalone

The storage of Ampidexalone must strictly follow regulatory guidelines to maintain its stability. The product is required to be protected from light and stored away from heat and sources of ignition. It must be kept in a tightly closed and properly labeled container. Certain formulations may require refrigeration (e.g., 2 C to 8 C), and the product must not be frozen.

Stability and Child Safety

After reconstitution, the solution's stability is limited; component stability data suggests use within approximately 24 hours, with colder storage often recommended. For safety, the medicine must be kept out of the reach of children and officially stored locked up.

Disposal

Unused or expired medicine must be disposed of via approved waste disposal plants or community drug take-back programs. Regulatory instructions require that the product avoid release to the environment and should not be poured down the drain or flushed down the toilet.

Ampidexalone